First, a broad understanding of the cellular events such as autophagy levels, ROS levels, and VPS4A and VPS4B levels can enable the strict screening of NSCLC patient populations suitable for ALO treatment. The gene discussed is VPS4A; the disease is non-small cell lung carcinoma.